Thermedical, a medical equipment manufacturer, has received $5.5m in a series A2 led by tech adviser Karl H. Johannsmeier.

MIT medtech spin-off Termedical has raised a $5.5m series A2 round led by tech adviser Karl H. Johannsmeier with participation by several angel investors.

Termedical’s chairman of the board Samuel H. Maslak joined Johannsmeier in leading the round.

The latest round of funding brings the total external investment raised in the US-based firm to $7m, and will be used to continue research into ventricular tachycardia, a potentially life-threatening heart condition, and the removal of solid tumours. First-in-man studies are due to take place later this year following recent Food & Drug Administration (FDA) clearance for the Massachusetts-based firm’s technology.

Samuel Maslak said: “The company has made excellent progress since my first investment last March, and I am optimistic about its growth potential. I believe this innovative technology will truly alter treatment for patients suffering from liver cancer and other solid tumors. It will also deliver an effective solution to cure ventricular tachycardia, a potentially life-threatening arrhythmia of the heart.”